<DOC>
	<DOCNO>NCT00149227</DOCNO>
	<brief_summary>The KYOTO HEART Study assess add-on effect valsartan , Angiotensin-Receptor Blocker , top conventional treatment high risk patient Japan hypertension term morbidity mortality .</brief_summary>
	<brief_title>Add-on Effects Valsartan Morbi- Mortality ( KYOTO HEART Study )</brief_title>
	<detailed_description>Although many report show ACE inhibitor angiotensin II receptor blocker ( ARB ) superior prevention cardiovascular event , previous data enough patient one risk factor anti-atherosclerotic effect ARB . In Japan , large-scale trial cardiovascular disease prevention , clarify whether evidence Western country could unqualifiedly apply Japanese patient long-range strategy . The KYOTO HEART Study assess add-on effect valsartan , Angiotensin-Receptor Blocker , top conventional treatment high risk patient hypertension term morbidity mortality .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Clinical diagnosis hypertension Clinical diagnosis one risk factor , diabetes , smoke habit , lipid metabolism abnormality , history ischemic heart disease ( IHD ) cerebrovascular disease , obesity ( BMI &gt; 25 ) , chronic heart failure ( NYHA IIIII ) , electrocardiogram ( ECG ) abnormality ( LVH ) Patients already administer ARB Patients IHD within 6 month percutaneous coronary intervention ( PCI ) , stable go implement PCI coronary artery bypass grafting ( CABG ) Severe/malignant/secondary hypertensive patient Pregnant woman woman childbearing potential History heart failure , unstable angina , myocardial infarction , PTCA , CABG within precede 6 month Arrhythmia need treat accompanied symptom , second third degree AV block Severe renal impairment ( Serum creatinine &gt; 3.0 mg/dl ) Severe hepatic impairment ( Hepatic failure , Cirrhosis , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>High risk hypertension</keyword>
	<keyword>Ischemic heart disease</keyword>
	<keyword>Angiotensin receptor blocker</keyword>
	<keyword>Cardiovascular mortality- morbidity</keyword>
	<keyword>KYOTO HEART Study</keyword>
</DOC>